Phase 2 Leukaemia Trial, Recruiting NCT05940961 Sponsor: Sheng-Li Xue, MD Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT05940961
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 15 to 65 years old
  • People diagnosed with a type of blood cancer called CD22+ B-cell acute lymphoblastic leukaemia (B-ALL), based on 2023 NCCN diagnostic standards
  • People with CD22+ B-ALL whose cancer has shown signs of returning (detected by a sensitive test called MRD) after a bone marrow/stem cell transplant — or, for those with a specific type called Ph+ ALL, people whose cancer did not respond to one or more second-generation targeted therapies (TKIs)
  • People with a general health and activity level rated below a certain threshold (ECOG score of less than 3, meaning able to carry out some daily activities) (confirm with trial site)
  • People expected to survive at least 3 months
  • People without serious heart, lung, liver, or kidney disease
  • People who are able to understand the trial and agree to take part voluntarily

Who may not be able to join:

  • People with a known allergy to the study drug or chemically similar drugs
  • People who are pregnant, breastfeeding, or of childbearing age who are unwilling to use effective contraception during the trial
  • People who currently have an active infection
  • People who are currently experiencing active bleeding
  • People who have had a blood clot, blockage in a blood vessel, brain bleed, or similar condition within the past year
  • People with a mental health condition or other circumstances that would prevent them from giving informed consent or following the study requirements
  • People with significantly abnormal liver function results or abnormal kidney function results on blood tests (confirm specific values with trial site)
  • People with a significant history of certain heart conditions, including abnormal heart rhythm measurements, irregular heartbeat, a particular type of heart block, a heart attack within the past year, heart failure, or coronary heart disease requiring medication
  • People who have had surgery on a major organ within the past six weeks
  • People with a history of drug abuse or long-term heavy alcohol use that could affect the trial results
  • People who have had an organ transplant (other than a bone marrow transplant)
  • People considered unsuitable for the trial by the treating doctor or investigator

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-0512-67781139

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sheng-Li Xue, MD
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

the rate of MRD-

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov